Recent News

• 01.12.2026 - CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
• 01.05.2026 - CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
• 12.22.2025 - CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
• 11.10.2025 - CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
• 11.08.2025 - CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

Recent Filings

• 01.12.2026 - 8-K Current report
• 01.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 144 Report of proposed sale of securities
• 12.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.22.2025 - 144 Report of proposed sale of securities
• 12.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.10.2025 - 8-K Current report
• 11.10.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.10.2025 - EX-99.1 EX-99.1